Xilio Therapeutics, Inc.

We’re pleased to announce that we will be presenting at #SITC24. We look forward to sharing preclinical data from our SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format, during the poster sessions on Saturday, November 9th. Read more at?https://lnkd.in/eppFnHGz We hope to see you at SITC:?https://lnkd.in/ggphnMEm

It was a pleasure to welcome Parexel’s Chief Patient Officer, Stacy Hurt ?? as well as Luke Rosen, founder of Rescue 7 Firefighters for Patients?and KIF1A.ORG, as speakers at our recent all-company meeting. Both Stacy and Luke, #ColorectalCancer advocates and survivors, shared their perspectives on patient-first clinical research and driving therapeutic solutions that make an impact. We had the honor to hear each of their stories from diagnosis to treatment, advocacy and parenting children with rare disorders. Their perspectives left a deep impression on the entire Xilio team, underscoring the critical need for new treatment options and how vitally important our work is. Testimonials like theirs spur our team to work even harder as we advance our pipeline of novel, tumor-activated I-O therapies. Thank you, Stacy and Luke, for joining us and for your courage and passion, and special thanks to our moderator, Tiffany Patrick, MPH, MBA, life science leader and global health advocate, for helping to facilitate this impactful conversation.

Alongside news of our Q2 2024 earnings and pipeline progress yesterday, we announced the promotion of?Christopher Frankenfield?to chief financial officer while continuing to serve in his role as chief operating officer. Chris has been integral to guiding Xilio's strategic growth since he joined us in 2021, and we are confident in his continued leadership as we advance our robust pipeline of tumor-activated immunotherapies to treat cancer. https://lnkd.in/eDzrgytg

Today, we reported our Q2 2024 financial results and initiation of enrollment in our Phase 2 clinical trial of XTX101 (aCTLA4) in combination with atezolizumab in patients with MSS CRC, as well as Phase 1B monotherapy dose expansion for XTX301 (IL12) in patients with advanced solid tumors. Read our press release to learn more:?https://lnkd.in/eDzrgytg

Xilio Chief Executive Officer?Rene Russo,?Pharm.D., will share her perspectives and industry experiences about elevating the patient voice during a Leadership Keynote conversation at this year’s Chief Patient Officer Summit hosted by Dynamic Global Events (DGE) on Tuesday, July 16 at 1:25 PM ET. This event is the industry’s largest forum for revolutionizing patient engagement strategy and emphasizes the understanding of patient community influence. Learn more and register:?https://lnkd.in/dAyD4uk

Today, we announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to our board of directors. Dr. Brennan and Dr. Shannon are well-accomplished industry veterans who bring deep leadership and drug development experience spanning all stages of drug development. We look forward to utilizing their expertise as we advance our pipeline of novel, tumor-activated I-O therapies. Read more: https://lnkd.in/eR3tF2EK

Investment Reports latest “New Era of Life Sciences” report in Newsweek recently highlighted innovations in immunotherapy, including Xilio’s geographic precision medicines. Our tumor-selective immunotherapies are designed to focus the immune system's tumor-destroying effect locally in tumor tissue but not in healthy tissues – by localizing activity to the tumor, we hope to overcome the toxicities of prior generations of immunotherapies. Read the interview with our President and CEO, Dr.?Rene Russo here:?https://lnkd.in/eDAe57en

Today, we reported our Q1 2024 financial results and highlighted continued progress across our pipeline of tumor-activated molecules. Read our press release to learn more: https://lnkd.in/egSWGTiz

We're pleased to have shared preclinical data from Xilio's first bispecific program, XTX501, a tumor-activated PD-1/IL-2 bispecific molecule at?#AACR24. The data presented suggest that XTX501 has the potential to improve upon the anti-tumor activity of the existing PD-1/PD-L1 immunotherapies while maintaining a favorable therapeutic index. Discover more from the poster below. https://lnkd.in/eJsrHCmk

At #AACR24, Xilio?will share?preclinical data from our first bispecific program, XTX501, a tumor-activated PD-1/IL-2 bispecific development candidate during this Sunday’s poster presentation session at 1:30 pm PT.?Learn more about our research at?https://xiliotx.com/.? #cancerresearch?#Xiliotx